ATE232399T1 - Verfahren zur modulierung des wachstums kollateraler arterien und / oder anderer arterien aus bestehenden arteriolen verbindungen - Google Patents

Verfahren zur modulierung des wachstums kollateraler arterien und / oder anderer arterien aus bestehenden arteriolen verbindungen

Info

Publication number
ATE232399T1
ATE232399T1 AT98924093T AT98924093T ATE232399T1 AT E232399 T1 ATE232399 T1 AT E232399T1 AT 98924093 T AT98924093 T AT 98924093T AT 98924093 T AT98924093 T AT 98924093T AT E232399 T1 ATE232399 T1 AT E232399T1
Authority
AT
Austria
Prior art keywords
arteries
growth
collateral
connections
mcp
Prior art date
Application number
AT98924093T
Other languages
English (en)
Inventor
Wolfgang Schaper
Wulf D Ito
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of ATE232399T1 publication Critical patent/ATE232399T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Liquid Crystal Display Device Control (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
AT98924093T 1997-04-04 1998-04-01 Verfahren zur modulierung des wachstums kollateraler arterien und / oder anderer arterien aus bestehenden arteriolen verbindungen ATE232399T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97105647 1997-04-04
PCT/EP1998/001891 WO1998044953A1 (en) 1997-04-04 1998-04-01 Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections

Publications (1)

Publication Number Publication Date
ATE232399T1 true ATE232399T1 (de) 2003-02-15

Family

ID=8226664

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98924093T ATE232399T1 (de) 1997-04-04 1998-04-01 Verfahren zur modulierung des wachstums kollateraler arterien und / oder anderer arterien aus bestehenden arteriolen verbindungen

Country Status (10)

Country Link
US (2) US6592862B1 (de)
EP (2) EP1304123A3 (de)
JP (1) JP2001519795A (de)
AT (1) ATE232399T1 (de)
CA (1) CA2284922A1 (de)
DE (1) DE69811348T2 (de)
DK (1) DK0969877T3 (de)
ES (1) ES2187972T3 (de)
PT (1) PT969877E (de)
WO (1) WO1998044953A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
WO1999017798A1 (en) * 1997-10-02 1999-04-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
US6749617B1 (en) 1997-11-04 2004-06-15 Scimed Life Systems, Inc. Catheter and implants for the delivery of therapeutic agents to tissues
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US6727349B1 (en) 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
US6329510B1 (en) 1999-01-29 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-CCR1 antibodies and methods of use therefor
AU4544600A (en) * 1999-04-06 2000-10-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Pharmaceutical compositions comprising circulating blood cells, preferably monocytes and uses thereof
AU2001261737A1 (en) * 2000-05-18 2001-11-26 Genetix Pharmaceuticals, Inc. Methods and compositions for promoting angiogenesis using monocytes
CA2409298A1 (en) * 2000-05-19 2001-11-29 The Government Of The United States Of America Methods for reducing tumor growth and metastasis by inhibiting mcp-1 activity
EP1383551B1 (de) * 2000-11-08 2010-07-14 Boston Scientific Limited Multilumen katheter und implantate zur verabreichung von therapeutischen substanzen an gewebe
ES2386775T3 (es) * 2001-07-23 2012-08-30 The Board Of Trustees Of The Leland Stanford Junior University Procedimientos y composiciones para la inhibición mediada por ARNi de la expresión génica en mamíferos
US10590418B2 (en) 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179078A (en) * 1989-05-12 1993-01-12 Dana Farber Cancer Institute Method of suppressing tumor formation in vivo
WO1995031467A1 (en) * 1994-05-16 1995-11-23 Human Genome Sciences, Inc. Monocyte chemotactic protein-4
WO1996026742A1 (en) 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US6544543B1 (en) * 2000-12-27 2003-04-08 Advanced Cardiovascular Systems, Inc. Periodic constriction of vessels to treat ischemic tissue

Also Published As

Publication number Publication date
EP0969877B1 (de) 2003-02-12
WO1998044953A1 (en) 1998-10-15
JP2001519795A (ja) 2001-10-23
DE69811348T2 (de) 2003-12-24
DE69811348D1 (de) 2003-03-20
EP0969877A1 (de) 2000-01-12
PT969877E (pt) 2003-06-30
US6592862B1 (en) 2003-07-15
CA2284922A1 (en) 1998-10-15
US20040023881A1 (en) 2004-02-05
ES2187972T3 (es) 2003-06-16
EP1304123A3 (de) 2003-11-19
EP1304123A2 (de) 2003-04-23
DK0969877T3 (da) 2003-03-24

Similar Documents

Publication Publication Date Title
ATE257392T1 (de) Verfahren zur modulierung der neovaskularisierung und/oder des wachstums von kollateraler arterien und / oder anderer arterien aus bestehenden arteriolären verbindungen
DE69811348D1 (de) Verfahren zur modulierung des wachstums kollateraler arterien und / oder anderer arterien aus bestehenden arteriolen verbindungen
EA199801044A1 (ru) Модуляторы регенерации тканей
DE60222910D1 (de) Vaccinia virus für diagnose und behandlung von tumoren
DE60020529D1 (de) Antikörper zur krebsbehandlung und -diagnose
ATE352559T1 (de) Verfahren zur verminderung der immunogenität von proteinen
BR0213786A (pt) Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
DE69128362D1 (de) Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit
ATE476654T1 (de) Plattform für protein-profiling
BR0207722A (pt) Material compósito de enxerto de medula óssea, método de preparação do mesmo, e, kit para a preparação do mesmo
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
ATE451390T1 (de) Polypeptide zur bindung an das b-lymphozyten- stimulatorische protein (blys)
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
SE8902532D0 (sv) Bestaemning av plasmaproteiner
ATE407677T1 (de) Gereinigte zubereitungen von 10-propargyl-10- deazaaminopterin und verfahren zu ihrer verwendung in der tumorbehandlung
ATE384263T1 (de) Verfahren zur bestimmung von biologischen agenzien in lebenden zielzellen
PT84089A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
ATE222122T1 (de) Verfahren zur tötung von zielzellen in geernteten zellpopulationen mit hilfe von zwei immunotoxinen
DE69510356D1 (de) Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
DK0649433T3 (da) Antigeniske regioner fra komplekser af tumorfrigivne partikler (TLP) og antistoffer mod sådanne.
DE69636041D1 (de) Nachweis von brusttumorvirus-artigen sequenzen in brustkrebs bei menschen
ATE312179T1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
PT86944A (pt) Verfahren zur isolierung von basalmembranproteinen aus menschlichen und tierischen geweben
DE60139150D1 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
DE69929683D1 (de) Antisense modulierung von lfa-3

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0969877

Country of ref document: EP

REN Ceased due to non-payment of the annual fee